Biologic properties and clinical uses of rifaximin

Bibliography

• Gomi H, Jiang ZD, Adachi JA, In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001;45:212-16
   PubMed Web of Science ®Google Scholar
• Jiang ZD, DuPont HL, La Rocco M, Garey KW. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol 2010;63:355-8
   PubMed Web of Science ®Google Scholar
• Sierra JM, Ruiz J, Navia MM, In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob Agents Chemother 2001;45:643-4
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP, In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-19
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Ericsson CD, Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001;33:1807-15
   PubMed Web of Science ®Google Scholar
• Taylor DN, Bourgeois AL, Ericsson CD, A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 2006;74:1060-6
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004;10:1009-11
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Okhuysen PC, A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005;142:805-12
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, DuPont HL. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 2010;35:278-81
   PubMed Web of Science ®Google Scholar
• Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother 2008;20:186-94
   PubMed Web of Science ®Google Scholar
• Brown EL, Xue Q, Jiang ZD, Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 2010;54:388-96
   PubMed Web of Science ®Google Scholar
• Ma X, Shah YM, Guo GL, Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007;322:391-8
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002;23:687-702
   PubMed Web of Science ®Google Scholar
• Dring MM, Goulding CA, Trimble VI, The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006;130:341-8; quiz 592
   PubMed Web of Science ®Google Scholar
• Langmann T, Moehle C, Mauerer R, Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004;127:26-40
   PubMed Web of Science ®Google Scholar
• Cheng J, Shah YM, Ma X, Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010;335:32-41
   Google Scholar
• Shah YM, Ma X, Morimura K, Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol 2007;292:G1114-22
   PubMed Web of Science ®Google Scholar
• Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-6
   PubMedGoogle Scholar
• Taylor DN, McKenzie R, Durbin A, Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 2008;52:1179-81
   PubMed Web of Science ®Google Scholar
• Rizzello F, Gionchetti P, Venturi A, Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998;54:91-3
   PubMed Web of Science ®Google Scholar
• Darkoh C, Lichtenberger LM, Ajami N, Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother 2010;54:3618-24
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-6
   PubMed Web of Science ®Google Scholar
• Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 2009;80:609-14
   PubMed Web of Science ®Google Scholar
• Adachi JA, Jiang ZD, Mathewson JJ, Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001;32:1706-9
   PubMed Web of Science ®Google Scholar
• DuPont HL, Reves RR, Galindo E, Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med 1982;307:841-4
   PubMed Web of Science ®Google Scholar
• Infante RM, Ericsson CD, Jiang ZD, Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004;2:135-8
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Belkind-Gerson J, Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007;5:451-6
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Farthing MJ, Expert review of the evidence base for self-therapy of travelers' diarrhea. J Travel Med 2009;16:161-71
   PubMedGoogle Scholar
• Casafont Morencos F, de las Heras Castano G, Martin Ramos L, Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1996;41:552-6
   PubMed Web of Science ®Google Scholar
• Morencos FC, de las Heras Castano G, Martin Ramos L, Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1995;40:1252-6
   PubMed Web of Science ®Google Scholar
• Sanchez E, Casafont F, Guerra A, Role of intestinal bacterial overgrowth and intestinal motility in bacterial translocation in experimental cirrhosis. Rev Esp Enferm Dig 2005;97:805-14
   PubMedGoogle Scholar
• Yang CY, Chang CS, Chen GH. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol 1998;33:867-71
   PubMed Web of Science ®Google Scholar
• Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis 2004;5:64-7
   PubMedGoogle Scholar
• Gupta A, Dhiman RK, Kumari S, Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010
   Google Scholar
• Haussinger D. Textbook of hepatology: from basic science to clinical practice: Chapter 2.3.7 Ammonia, urea production and pH regulation. 3rd edition. Blackwell Publishing, Victoria, Australia; 2007
   Google Scholar
• Mas A, Rodes J, Sunyer L, Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-8
   PubMed Web of Science ®Google Scholar
• Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-8
   PubMedGoogle Scholar
• Marchese A, Salerno A, Pesce A, In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000;46:253-66
   PubMed Web of Science ®Google Scholar
• Bass NM, Mullen KD, Sanyal A, Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-81
   PubMed Web of Science ®Google Scholar
• Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;52:737-41
   PubMed Web of Science ®Google Scholar
• Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-8
   PubMed Web of Science ®Google Scholar
• Gunnarsdottir SA, Sadik R, Shev S, Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003;98:1362-70
   PubMed Web of Science ®Google Scholar
• Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852-8
   PubMed Web of Science ®Google Scholar
• Peralta S, Cottone C, Doveri T, Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol 2009;15:2628-31
   PubMed Web of Science ®Google Scholar
• Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006;52:89-95
   PubMedGoogle Scholar
• Esposito I, de Leone A, Di Gregorio G, Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 2007;13:6016-21
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Scarpellini E, Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008;103:2031-5
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Gabrielli M, Lauritano CE, High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007;25:781-6
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Lupascu A, Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-5
   PubMed Web of Science ®Google Scholar
• Pimentel M, Mayer AG, Park S, Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 2003;48:86-92
   PubMed Web of Science ®Google Scholar
• Azpiroz F, Bouin M, Camilleri M, Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007;19:62-88
   PubMedGoogle Scholar
• Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr 2007;45(Suppl 2):S115-19
   PubMedGoogle Scholar
• Chadwick VS, Chen W, Shu D, Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J, The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-63
   PubMed Web of Science ®Google Scholar
• Colecchia A, Vestito A, Pasqui F, Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007;13:264-9
   PubMed Web of Science ®Google Scholar
• D'Inca R, Pomerri F, Vettorato MG, Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther 2007;25:771-9
   PubMed Web of Science ®Google Scholar
• Latella G, Pimpo MT, Sottili S, Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003;18:55-62
   PubMed Web of Science ®Google Scholar
• Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995;9:33-9
   PubMedGoogle Scholar
• Kean BH. The diarrhea of travelers to Mexico. Summary of five-year study. Ann Intern Med 1963;59:605-14
   PubMed Web of Science ®Google Scholar
• Kean BH, Waters S. The diarrhea of travelers. I. Incidence in travelers returning to the United States from Mexico. AMA Arch Ind Health 1958;18:148-50
   PubMedGoogle Scholar
• Travelers' diarrhea: National Institutes of Health Consensus Development Conference. Bethesda, Maryland, January 28 - 30, 1985. Rev Infect Dis 1986;8(Suppl 2):S109-233
   Google Scholar
• Martinez-Sandoval F, Ericsson CD, Jiang ZD, Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med 2010;17:111-17
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Farthing MJ, Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med 2009;16:149-60
   PubMedGoogle Scholar
• Garey KW, Salazar M, Shah D, Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2008;42:827-35
   PubMed Web of Science ®Google Scholar
• Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009;43:91-3
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Patel U, Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009;15:290-1
   PubMed Web of Science ®Google Scholar
• Bibiloni R, Mangold M, Madsen KL, The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006;55:1141-9
   PubMed Web of Science ®Google Scholar
• Sokol H, Seksik P, Rigottier-Gois L, Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:106-11
   PubMed Web of Science ®Google Scholar
• van Nuenen MH, Venema K, van der Woude JC, Kuipers EJ. The metabolic activity of fecal microbiota from healthy individuals and patients with inflammatory bowel disease. Dig Dis Sci 2004;49:485-91
   PubMed Web of Science ®Google Scholar
• Isaacs KL, Sandler RS, Abreu M, Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007;13:1250-5
   PubMed Web of Science ®Google Scholar
• Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008;8:26
   PubMed Web of Science ®Google Scholar
• Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010;6:CD001176
   PubMedGoogle Scholar
• Ruiz J, Mensa L, Pons MJ, Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother 2008;61:1016-19
   PubMedGoogle Scholar
• Ouyang-Latimer J, Jafri S, VanTassel A, In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala and India, 2006-2008, Antimicrob Agents Chemother 29 Nov 2010. [Epub ahead of print] PMID: 21115800
   Google Scholar
• De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986;12:979-81
   PubMedGoogle Scholar
• Soro O, Pesce A, Raggi M, Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect 1997;3:147-51
   PubMedGoogle Scholar
• Lucchesi M, Marchi E, Venturini AP. Antimycobacterial activity of rifaximin (L/105) in experimental tuberculosis in the guinea pig. Chemioterapia 1984;3:371-2
   PubMedGoogle Scholar
• Malvisi Stracciari J, Venturini AP, Anfossi P, Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin. Chemioterapia 1987;6:82-4
   PubMedGoogle Scholar
• Steffen R, Sack DA, Riopel L, Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003;98:1073-8
   PubMed Web of Science ®Google Scholar
• DuPont HL, Haake R, Taylor DN, Rifaximin treatment of pathogen-negative travelers' diarrhea. J Travel Med 2007;14:16-19
   PubMedGoogle Scholar
• Neff G, Zacharias V, Kaiser TE, Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series. Liver Transpl 2010;16:960-3
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Morselli C, Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 2005;51(Suppl 1):96-102
   PubMedGoogle Scholar
• Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006;12:335
   PubMed Web of Science ®Google Scholar
• Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009;49:400-4
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Campieri M, Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23:1117-25
   PubMed Web of Science ®Google Scholar